Landscapes / Targets
mTOR
16 drugs act on mTOR, in 25 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs16
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | Jan 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) and 5 more | ||||
| Open drug page | |||||
— |
Approved in EU | 1 Feb 2028Phase 3 trial completes | |||
| Next date | 1 Feb 2028 · Phase 3 trial completes | ||||
| Also tested for | Peripheral Artery Disease, Critical Limb Ischemia | ||||
| Open drug page | |||||
— |
Approved in other | Dec 2030Phase 4 trial completes | |||
| Next date | Dec 2030 · Phase 4 trial completes | ||||
| Also tested for | Heart Transplant | ||||
| Open drug page | |||||
— |
Approved in EU | — | |||
| Also tested for | Longevity, GLP-1 and 2 more | ||||
| Open drug page | |||||
RaparoBellnot checked |
— |
On the market | — | ||
| Also tested for | Kidney Transplantation | ||||
| Open drug page | |||||
— |
Phase 3 | Aug 2027Phase 2 trial completes | |||
| Next date | Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Pachyonychia Congenita, Angiokeratomas | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Sep 2029Phase 3 trial completes | |||
| Next date | 30 Sep 2029 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumor, Gastric Type Adenocarcinoma (GAS) With STK11 Mutation and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Endometrial Cancer, Endometrioid Tumor and 4 more | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Major Depressive Disorder (MDD) | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Sep 2027Phase 2 trial completes | |||
| Next date | 1 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Tuberous Sclerosis Complex, Epilepsy | ||||
| Open drug page | |||||
— |
Phase 1/2 | 15 Oct 2027Phase 1/2 trial completes | |||
| Next date | 15 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Canities, Grey Hair | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2027Phase 2 trial completes | |||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Kidney Transplantation | ||||
| Open drug page | |||||
— |
Faeth Therapeutics +1 |
Phase 2 | Sep 2028Phase 2 trial completes | ||
| Next date | Sep 2028 · Phase 2 trial completes | ||||
| Also tested for | Endometrial Cancer, HR+ HER2- Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | 1 Sep 2030Phase 1/2 trial completes | |||
| Next date | 1 Sep 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Endometrial Neoplasms, Soft Tissue Sarcoma (STS) and 4 more | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 2 | — | ||
| Also tested for | Muscle Invasive Bladder Cancer, Non-Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 15 of 16 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026